Opaleye Management 13F annual report
Opaleye Management is an investment fund managing more than $222 million ran by James Silverman. There are currently 47 companies in Mr. Silverman’s portfolio. The largest investments include Harrow Health and Ocular Therapeutix Inc, together worth $48.3 million.
$222 million Assets Under Management (AUM)
As of 8th August 2022, Opaleye Management’s top holding is 3,332,732 shares of Harrow Health currently worth over $24.3 million and making up 10.9% of the portfolio value.
Relative to the number of outstanding shares of Harrow Health, Opaleye Management owns more than 0.1% of the company.
In addition, the fund holds 5,974,800 shares of Ocular Therapeutix Inc worth $24 million, whose value fell 1.8% in the past six months.
The third-largest holding is Codexis worth $13.5 million and the next is Crinetics Pharmaceuticals Inc worth $12.5 million, with 671,300 shares owned.
Currently, Opaleye Management's portfolio is worth at least $222 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Opaleye Management
The Opaleye Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, James Silverman serves as the President at Opaleye Management.
Recent trades
In the most recent 13F filing, Opaleye Management revealed that it had opened a new position in
Inhibrx and bought 590,000 shares worth $6.7 million.
This means they effectively own approximately 0.1% of the company.
Inhibrx makes up
3.2%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Harrow Health by buying
41,389 additional shares.
This makes their stake in Harrow Health total 3,332,732 shares worth $24.3 million.
Harrow Health dropped approximately 0.1% in the past year.
On the other hand, there are companies that Opaleye Management is getting rid of from its portfolio.
Opaleye Management closed its position in Bicycle Therapeutics plc on 15th August 2022.
It sold the previously owned 175,000 shares for $7.68 million.
James Silverman also disclosed a decreased stake in Codexis by approximately 0.1%.
This leaves the value of the investment at $13.5 million and 1,288,450 shares.
One of the smallest hedge funds
The two most similar investment funds to Opaleye Management are Bcs Wealth Management and Rv Capital Ag. They manage $222 million and $222 million respectively.
James Silverman investment strategy
Opaleye Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 93.2% of
the total portfolio value.
The fund focuses on investments in the United States as
70.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
13% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $616 million.
The complete list of Opaleye Management trades based on 13F SEC filings
These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Harrow Health, Inc. |
1.26%
3,332,732
|
$24,262,000 | 10.94% |
| Ocular Therapeutix Inc |
No change
5,974,800
|
$24,019,000 | 10.83% |
| Codexis Inc. |
4.20%
1,288,450
|
$13,477,000 | 6.07% |
| Crinetics Pharmaceuticals Inc |
3.13%
671,300
|
$12,520,000 | 5.64% |
| Cytokinetics Inc |
25.58%
302,500
|
$11,885,000 | 5.36% |
| TELA Bio, Inc. |
244.52%
1,643,367
|
$11,520,000 | 5.19% |
| Protara Therapeutics Inc |
0.38%
2,684,167
|
$8,885,000 | 4.00% |
| TRACON Pharmaceuticals Inc |
30.75%
4,125,322
|
$8,251,000 | 3.72% |
| Kiniksa Pharmaceuticals Ltd |
26.81%
814,250
|
$7,890,000 | 3.56% |
| Bicycle Therapeutics plc |
Closed
175,000
|
$7,679,000 | |
| Merus N.V |
No change
338,000
|
$7,652,000 | 3.45% |
| Keros Therapeutics, Inc. |
3.86%
276,000
|
$7,626,000 | 3.44% |
| Inhibrx, Inc. |
Opened
590,000
|
$6,697,000 | 3.02% |
| Eton Pharmaceuticals, Inc. |
3.50%
2,462,500
|
$6,452,000 | 2.91% |
| Protagonist Therapeutics Inc |
Closed
251,500
|
$5,956,000 | |
| XOMA Corp |
2.93%
263,050
|
$5,861,000 | 2.64% |
| Reata Pharmaceuticals Inc |
54.85%
183,750
|
$5,584,000 | 2.52% |
| Cutera Inc |
Opened
147,700
|
$5,539,000 | 2.50% |
| Mersana Therapeutics Inc |
47.46%
1,047,000
|
$4,837,000 | 2.18% |
| Vaxcyte, Inc. |
9.95%
190,000
|
$4,134,000 | 1.86% |
| Stereotaxis, Inc. |
12.34%
2,099,971
|
$3,864,000 | 1.74% |
| Edgewise Therapeutics Inc |
48.98%
451,400
|
$3,593,000 | 1.62% |
| Semler Scientific Inc |
Closed
70,000
|
$3,469,000 | |
| 908 Devices Inc. |
No change
166,406
|
$3,426,000 | 1.54% |
| Fulcrum Therapeutics Inc |
Closed
136,000
|
$3,216,000 | |
| Chimerix Inc |
75.78%
1,430,000
|
$2,974,000 | 1.34% |
| Fortress Biotech Inc |
13.41%
3,247,180
|
$2,727,000 | 1.23% |
| Celldex Therapeutics Inc. |
53.96%
90,000
|
$2,426,000 | 1.09% |
| Synlogic Inc |
Closed
984,200
|
$2,362,000 | |
| Liquidia Corp |
191.67%
521,500
|
$2,274,000 | 1.02% |
| 4D Molecular Therapeutics Inc. |
No change
325,000
|
$2,269,000 | 1.02% |
| Proqr Therapeutics Nv |
12.99%
2,740,000
|
$2,131,000 | 0.96% |
| UroGen Pharma Ltd |
Opened
238,670
|
$1,955,000 | 0.88% |
| Ginkgo Bioworks Holdings Inc |
12.34%
815,000
|
$1,940,000 | 0.87% |
| Verastem Inc |
31.61%
1,590,000
|
$1,844,000 | 0.83% |
| Larimar Therapeutics, Inc. |
1.15%
932,814
|
$1,828,000 | 0.82% |
| Hyperfine Inc |
No change
763,075
|
$1,702,000 | 0.77% |
| Rhythm Pharmaceuticals Inc. |
Opened
362,000
|
$1,502,000 | 0.68% |
| Modular Medical Inc |
3.50%
275,422
|
$1,427,000 | 0.64% |
| Impel Pharmaceuticals Inc |
Opened
144,642
|
$1,348,000 | 0.61% |
| AVEO Pharmaceuticals Inc |
Closed
240,000
|
$1,342,000 | |
| Graphite Bio Inc |
80.04%
460,000
|
$1,265,000 | 0.57% |
| Journey Medicine Corp |
266.77%
245,733
|
$919,000 | 0.41% |
| NuCana plc |
Closed
878,700
|
$878,000 | |
| Repare Therapeutics Inc. |
Closed
55,678
|
$793,000 | |
| Sutro Biopharma Inc |
Closed
89,980
|
$740,000 | |
| Neoleukin Therapeutics, Inc. |
22.78%
610,000
|
$628,000 | 0.28% |
| Macrogenics Inc |
44.66%
208,300
|
$614,000 | 0.28% |
| Neuropace Inc |
Opened
90,100
|
$446,000 | 0.20% |
| Forma Therapeutics Holdings, Inc., |
Opened
58,700
|
$404,000 | 0.18% |
| OptiNose Inc |
Opened
90,970
|
$333,000 | 0.15% |
| Marinus Pharmaceuticals Inc |
Opened
68,900
|
$333,000 | 0.15% |
| Avalo Therapeutics Inc |
69.06%
450,000
|
$225,000 | 0.10% |
| Theseus Pharmaceuticals Inc |
Opened
32,300
|
$179,000 | 0.08% |
| Lumos Pharma Inc |
Opened
21,520
|
$166,000 | 0.07% |
| Biolinerx Ltd |
No change
16,667
|
$21,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 56 holdings | |||
Hedge funds similar to Opaleye Management
- Marathon Trading Investment Management
- Sawyer , Inc
- Sovereign Investment Advisors
- Householder Estate & Retirement Specialist
- Ml & R Wealth Management
- Beck Capital Management
- Rv Capital Ag
- Bcs Wealth Management
- Dfpg Investments
- Virtus Etf Advisers
- West Oak Capital
- Lantz
- Bay Harbor Wealth Management
- Sentry Investment Management